In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

D J Diekema; M A Pfaller; S A Messer; A Houston; R J Hollis; G V Doern; R N Jones

doi:10.1128/AAC.43.9.2236

Back

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

Journal article

Open access

Peer reviewed

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

D J Diekema, M A Pfaller, S A Messer, A Houston, R J Hollis, G V Doern and R N Jones

Antimicrobial agents and chemotherapy, Vol.43(9), pp.2236-2239

09/1999

DOI: 10.1128/AAC.43.9.2236

PMCID: PMC89453

PMID: 10471571

Files and links (1)

url

https://doi.org/10.1128/AAC.43.9.2236View

Published (Version of record) Open Access

Abstract

We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates of Candida spp. collected from SENTRY participating hospitals during 1997 and 1998. Overall, BMS-207147 was the most active azole against all Candida spp. While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp. that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.

North America

Latin America

Antifungal Agents - pharmacology

Fluconazole - pharmacology

Humans

Candida - isolation & purification

Itraconazole - pharmacology

Dose-Response Relationship, Drug

Microbial Sensitivity Tests

Triazoles - pharmacology

Thiazoles - pharmacology

Candida - drug effects

Population Surveillance

Details

Title: Subtitle: In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
Creators: D J Diekema - Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA. daniel-diekema@uiowa.edu
M A Pfaller
S A Messer
A Houston
R J Hollis
G V Doern
R N Jones
Contributors: Sentry Participants Group (Author)
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.43(9), pp.2236-2239
Publisher: United States
DOI: 10.1128/AAC.43.9.2236
PMID: 10471571
PMCID: PMC89453
ISSN: 0066-4804
eISSN: 1098-6596
Language: English
Date published: 09/1999
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986257602771

Metrics

11 Record Views

31 Times Cited - Web of Science